SR141716A / rimonabant, a CB1 receptor antagonist: molecular mechanisms & dependencies

How nutrients influence it

Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.

Human evidence only

How nutrients reach it in more than one step

Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.

Tracing routes…

What it does

Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.

Recorded relationships

What it acts on

The CB1 antagonist SR141716A attenuated the memory impairment produced by THC or by anandamide.
SR141716A / rimonabant, a CB1 receptor antagonist → Spatial memory performance source_derived_draftungraded
Experimental context and source evidence
availability_state
machinery_impairment Imported condition classification; unverified.
evidence_span
{"source_cache": "artifacts/thc-research/9862397.abstract.txt", "locator": "Indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "59e00778f9e8b2a2aba64063224de431ef098aaffcf26dca95fd9ddb36981a1f", "start_char": 0, "end_char": 1576, "text_sha256": "59e00778f9e8b2a2aba64063224de431ef098aaffcf26dca95fd9ddb36981a1f"}
experimental_model
Memory impairment by THC or anandamide with SR141716A pretreatment
exposure
THC or anandamide with a CB1 antagonist
limitations
Shows the antagonist rescues the impairment for both the drug and the natural ligand.
nutrient_topic
THC research collection; topical membership is not evidence of a direct clinical effect, and THC is recorded separately from the endocannabinoids it imitates. · Delta-9-tetrahydrocannabinol / THC
organism
Rat
plain_language
Blocking the receptor protects the memory, whichever agonist caused the problem.
primary_references
[thc-p9862397] The cannabinoid CB1 receptor antagonist SR141716A attenuates the memory impairment produced by delta9-tetrahydrocannabinol or anandamide. (1998). https://pubmed.ncbi.nlm.nih.gov/9862397/ DOI: 10.1007/s002130050733
tissue_or_cell_type
Behaviour
trigger_kind
machinery_impairment Imported condition classification; unverified.
THC: the cannabinoid receptors, the endocannabinoid system it occupies, what the drug does, and the dietary fat it is built from (2026-09-21) · lines 452–463
AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Memory impairment by THC or anandamide with SR141716A pretreatment · source_derived_draft · unverified_draft
### thc-antagonist-rescues-memory The CB1 antagonist SR141716A attenuated the memory impairment produced by THC or by anandamide. Condition category: machinery_impairment nutrient_topic: THC research collection; topical membership is not evidence of a direct clinical effect, and THC is recorded separately from the endocannabinoids it imitates. plain_language: Blocking the receptor protects the memory, whichever agonist caused the problem. organism: Rat tissue_or_cell_type: Behaviour experimental_model: Memory impairment by THC or anandamide with SR141716A pretreatment limitations: Shows the antagonist rescues the impairment for both the drug and the natural ligand. exposure: THC or anandamide with a CB1 antagonist evidence_span: {"source_cache": "artifacts/thc-research/9862397.abstract.txt", "locator": "Indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "59e00778f9e8b2a2aba64063224de431ef098aaffcf26dca95fd9ddb36981a1f", "start_char": 0, "end_char": 1576, "text_sha256": "59e00778f9e8b2a2aba64063224de431ef098aaffcf26dca95fd9ddb36981a1f"} [thc-p9862397] The cannabinoid CB1 receptor antagonist SR141716A attenuates the memory impairment produced by delta9-tetrahydrocannabinol or anandamide. (1998). https://pubmed.ncbi.nlm.nih.gov/9862397/ DOI: 10.1007/s002130050733
Complete structured claim and evidence
Appetite suppression and weight loss followed administration of the cannabinoid antagonist SR141716.
SR141716A / rimonabant, a CB1 receptor antagonist → Food intake source_derived_draftungraded
Experimental context and source evidence
evidence_span
{"source_cache": "artifacts/thc-research/9718088.abstract.txt", "locator": "Indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "4714909d64a1c671c1c3dcec0496b80cc6a09e0a8d0368ed6b8be8aa284456e2", "start_char": 0, "end_char": 590, "text_sha256": "4714909d64a1c671c1c3dcec0496b80cc6a09e0a8d0368ed6b8be8aa284456e2"}
experimental_model
The CB1 antagonist SR141716 given for appetite and body weight measurement
exposure
SR141716 administration with food intake and weight measurement
limitations
Establishes that blocking the receptor suppresses appetite, which is the mirror of the drug effect. Rimonabant was later withdrawn for psychiatric adverse effects, which is not in this record.
nutrient_topic
THC research collection; topical membership is not evidence of a direct clinical effect, and THC is recorded separately from the endocannabinoids it imitates. · Delta-9-tetrahydrocannabinol / THC
organism
Rodent
plain_language
Blocking the receptor takes hunger away, which is why the drug increases it.
primary_references
[thc-p9718088] Appetite suppression and weight loss after the cannabinoid antagonist SR 141716. (1998). https://pubmed.ncbi.nlm.nih.gov/9718088/ DOI: 10.1016/s0024-3205(98)00322-1
tissue_or_cell_type
Whole body
THC: the cannabinoid receptors, the endocannabinoid system it occupies, what the drug does, and the dietary fat it is built from (2026-09-21) · lines 491–502
AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · The CB1 antagonist SR141716 given for appetite and body weight measurement · source_derived_draft · unverified_draft
### thc-antagonist-suppresses-appetite Appetite suppression and weight loss followed administration of the cannabinoid antagonist SR141716. Condition category: normal nutrient_topic: THC research collection; topical membership is not evidence of a direct clinical effect, and THC is recorded separately from the endocannabinoids it imitates. plain_language: Blocking the receptor takes hunger away, which is why the drug increases it. organism: Rodent tissue_or_cell_type: Whole body experimental_model: The CB1 antagonist SR141716 given for appetite and body weight measurement limitations: Establishes that blocking the receptor suppresses appetite, which is the mirror of the drug effect. Rimonabant was later withdrawn for psychiatric adverse effects, which is not in this record. exposure: SR141716 administration with food intake and weight measurement evidence_span: {"source_cache": "artifacts/thc-research/9718088.abstract.txt", "locator": "Indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "4714909d64a1c671c1c3dcec0496b80cc6a09e0a8d0368ed6b8be8aa284456e2", "start_char": 0, "end_char": 590, "text_sha256": "4714909d64a1c671c1c3dcec0496b80cc6a09e0a8d0368ed6b8be8aa284456e2"} [thc-p9718088] Appetite suppression and weight loss after the cannabinoid antagonist SR 141716. (1998). https://pubmed.ncbi.nlm.nih.gov/9718088/ DOI: 10.1016/s0024-3205(98)00322-1
Complete structured claim and evidence

The events it takes part in

A mechanism often involves more than two components. These are the full events, with every participant and its role.

Situations it appears in

Low-supply and faulty-machinery situations recorded in the chapters where this component plays a part.

In the sources

Preserved passages that mention this component, quoted exactly. Open one to read it in context.

Open hypotheses

Proposed ideas that involve this component. They are labeled as hypotheses and do not change any recorded statement.

This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.

SR141716A / rimonabant, a CB1 receptor antagonist